- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07708025
Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients
Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients: A Prospective Analysis
People with heart failure often have anemia caused by low iron levels. Ongoing inflammation in heart failure can impair iron absorption, making oral iron therapy less effective.
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are medications used to treat heart failure. In addition to their cardiovascular benefits, these drugs may improve iron metabolism and support red blood cell production.
This study evaluates whether patients with heart failure and iron deficiency anemia who are receiving SGLT2i therapy respond to treatment with oral iron. Participants receive oral iron for three to four months, followed by a short period without treatment. Blood tests are used to assess changes in hemoglobin levels.
The objective of this study is to determine whether treatment with SGLT2i enhances the response to oral iron in patients with heart failure and iron deficiency anemia.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
Porto, Portugal, 4200-319
- Unidade Local de Saúde São João
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 1) Previous diagnosis of heart failure, irrespective of ejection fraction;
- 2) Iron deficiency anemia defined as hemoglobin <13 g/dL in men or <12 g/dL in women, with transferrin saturation (TSAT) <20%;
- 3) Ongoing treatment with an SGLT2 inhibitor (SGLT2i) for more than 3 months at the time of enrollment.
Exclusion Criteria:
- 1) Concomitant use of intravenous iron, erythropoiesis-stimulating agents (ESAs), red blood cell transfusions, or other blood products within 3 months before enrollment;
- 2) Severe anemia, defined as hemoglobin <7 g/dL or clinical indication for transfusion;
- 3) Relevant intercurrent illnesses associated with inflammatory response (e.g., infection, acute kidney injury, or acute decompensated heart failure) within 3 months before enrollment;
- 4) Confirmed or suspected active bleeding;
- 5) End-stage renal disease or receiving renal replacement therapy;
- 6) History of any type of active cancer;
- 7) History of solid or non-solid organ transplantation.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Oral iron supplementation
either hydroxide polymaltose [Ferrum Haussman®] or ferrous sulfate [Ferro Gradumet®] |
Oral iron supplementation administered at the treating physician's discretion
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Hemoglobin Levels
Tidsram: Baseline, 3-4 months, and 5-6 months
|
Change from baseline in hemoglobin levels measured by laboratory blood tests |
Baseline, 3-4 months, and 5-6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Hematocrit
Tidsram: Baseline, 3-4 months, and 5-6 months
|
Change from baseline in hematocrit measured by laboratory blood tests |
Baseline, 3-4 months, and 5-6 months
|
|
Change in Transferrin Saturation
Tidsram: Baseline, 3-4 months, and 5-6 months
|
Change from baseline in transferrin saturation measured by laboratory blood tests. |
Baseline, 3-4 months, and 5-6 months
|
|
Change in Serum Iron
Tidsram: Baseline, 3-4 months, and 5-6 months
|
Change from baseline in serum iron measured by laboratory blood tests. |
Baseline, 3-4 months, and 5-6 months
|
|
Change in Ferritin
Tidsram: Baseline, 3-4 months, and 5-6 months
|
Change from baseline in ferritin measured by laboratory blood tests. |
Baseline, 3-4 months, and 5-6 months
|
|
Change in Total Iron-Binding Capacity (TIBC)
Tidsram: Baseline, 3-4 months, and 5-6 months
|
Change from baseline in TIBC measured by laboratory blood tests. |
Baseline, 3-4 months, and 5-6 months
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: João P. Ferreira, PhD. MD., Universidade do Porto
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Oral iron & SGLT2i HF
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .